Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Mechanism of action behind the pain-relief effects of extracellular vesicles in microfragmented adipose tissue: an in vitro and in vivo study.

De Francesco F., Ferroni L., Zanolla I., Sileo L., Cavaleri MP., Fordellone M.

Prospective Study with a reported sample of 25 on Osteoarthritis, Chronic Wound, Chronic Inflammation, published in J Transl Med (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Transl Med (2025)
Country
England
Reported sample size
25
Source database
PubMed
PMID
40826359
PMCID
PMC12362883
DOI
10.1186/s12967-025-06930-4
Citations
2

Abstract (original English)

Background Trapeziometacarpal osteoarthritis (TMC OA) is a prevalent and debilitating condition that impairs hand functionality and reduces quality of life. Current treatments including conservative measures such as splinting and anti-inflammatory medications, as well as surgical interventions often exhibit limited efficacy or involve invasive procedures. Novel therapeutic approaches are necessary to address the pain and functional limitations experienced by affected patients. Methods This study investigates the potential of extracellular vesicles (EVs) derived from autologous microfragmented adipose tissue (aMAT) as a minimally invasive treatment for TMC OA. EVs were characterized using morphological, proteomic, and functional analyses, revealing their ability to modulate cellular processes through proteins associated with extracellular matrix organization, wound healing, and inflammation regulation. Results Functional studies demonstrated that EVs modulate calcium signaling and mitochondrial activity, enhancing cellular bioenergetics and mitigating inflammation-induced dysfunction. In a clinical study with 25 patients diagnosed with TMC OA (Eaton Stage II), aMAT-derived EVs demonstrated significant benefits. Pain scores, measured by the numeric rating scale, improved substantially both at rest and during activity. Functional assessments, including the Michigan Hand Outcomes Q

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansExtracellular VesiclesAdipose TissueFemaleMiddle AgedMaleOsteoarthritisPain ManagementPainAged

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research